05/10/2026
Team Cure Cholangio is excited to share that with your generous support we funded another research fellowship grant this year. This years research fellowship grant honors Steve Wilger and Hayes Calvin, two incredible warriors stolen way too soon. The research fellowship grant was awarded to Xue Wang, at the University of Hawaii Cancer Center. Here is information about the research we are funding! so exciting! more research is more hope!
Title: YAP Inhibition–Based Combination Immunotherapy for Intrahepatic Cholangiocarcinoma
Intrahepatic cholangiocarcinoma (ICC) is a deadly liver cancer that weakens the body’s immune defenses and prevents immune cells from attacking the tumor. The most common immunotherapy, called immune checkpoint inhibitor–based combination therapy, helps some patients but is not very effective overall. To improve treatment, we need to understand why ICC tumors are able to suppress the body’s immune response. Our research has identified a protein called YAP that helps ICC tumors avoid being attacked by the immune system. When we turned off YAP in a mouse model of ICC, the tumors became smaller and more immune cells, especially T cells, entered the tumor. In patients, tumors with higher YAP activity had fewer T cells, suggesting that YAP makes the tumor environment more resistant to immune attack. Importantly, when YAP inhibition was combined with an immunotherapy drug, this approach effectively suppressed tumor growth. We also found that YAP controls certain molecules that influence how immune cells behave in the tumor. Together, these findings suggest that YAP activation helps create an environment in the tumors that weakens the body’s immune response. Based on these results, our research aims to understand how YAP drives this immune-suppressive environment in ICC and to test whether combining a YAP inhibitor with immunotherapy can more effectively control tumor growth. This project has strong potential to lead to new treatment strategies that could improve outcomes for patients with this aggressive and often fatal liver cancer.